Pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Clobetasol proprionate should only be used in pregnancy if the potential benefit justifies the potential risk to the fetus. The minimum quantity should be used for the minimum duration.
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low doses. Some have also been shown to be teratogenic after dermal application to laboratory animals. Clobetasol proprionate has greater teratogenic potential than other less potent steroids.
Lactation: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when clobetasol proprionate is administered to a breastfeeding woman.
If used during lactation, clobetasol should not be applied to the breasts to avoid accidental ingestion by the infant.